Thomas Lahiri
Professor, Pediatrics
Director, Vermont Cystic Fibrosis Center
Division Chief, Pediatric Pulmonology
- M.D., University of Connecticut School of Medicine, Farmington, CT
- B.S., McGill University, Montreal, Quebec, Canada
- Internship/Residency, Pediatrics, University of Vermont, Burlington, VT
- Fellowship, Pediatric Pulmonology, Children's Hospital, Boston, MA
BIO
Thomas Lahiri is a Professor of Pediatrics at the Larner College of Medicine and the Division Chief of Pediatric Pulmonology at UVM Health/Golisano Children's Hospital. His clinical areas of interest include cystic fibrosis, airway and aerodigestive orders, and asthma. He serves as the principal investigator for several pediatric clinical trials in cystic fibrosis and asthma.
Courses
First Patient (orientation) CRR: Pediatric Pulmonology
Awards and Achievements
- 2006 Nominated for Kroepsch-Maurice Excellence in Teaching Award (Assistant Professor level)
- 2003 UVM Pediatric Resident Teaching Award
- 2013 UVM Pediatric Resident Teaching Award
- 2014 UVM Pediatric Resident Teaching Award
- 2014 University of Vermont Medical Center GME Teacher of the Year
- 2017 Nominated, UVM Pediatric Resident Subspecialty Teacher of the Year
- 2025 Nominated, UVM GME Teacher of the Year
Bio
Thomas Lahiri is a Professor of Pediatrics at the Larner College of Medicine and the Division Chief of Pediatric Pulmonology at UVM Health/Golisano Children's Hospital. His clinical areas of interest include cystic fibrosis, airway and aerodigestive orders, and asthma. He serves as the principal investigator for several pediatric clinical trials in cystic fibrosis and asthma.
Courses
First Patient (orientation) CRR: Pediatric Pulmonology
Awards and Achievements
- 2006 Nominated for Kroepsch-Maurice Excellence in Teaching Award (Assistant Professor level)
- 2003 UVM Pediatric Resident Teaching Award
- 2013 UVM Pediatric Resident Teaching Award
- 2014 UVM Pediatric Resident Teaching Award
- 2014 University of Vermont Medical Center GME Teacher of the Year
- 2017 Nominated, UVM Pediatric Resident Subspecialty Teacher of the Year
- 2025 Nominated, UVM GME Teacher of the Year
Select Publications
- Green DM, Lahiri T, Raraigh KS, Ruiz F, Spano J, Antos N, Bonitz L, Christon L, Gregoire-Bottex M, Hale J, Langfelder-Schwind E, La Parra Perez A, Maguiness K, Massie J, McElroy-Barker E, McGarry M, Mercier A, Munck A, Oliver K, Self S, Singh K, Smiley M, Snodgrass S, Tluczek A, Tuley P, Lomas P, Wong E, Hempstead SE, Faro A, Ren CL. Cystic Fibrosis Foundation evidence-based guidelines for the management of cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis. Pediatrics 2024:153(5):e2023064657. PMID: 38577740.
- Lahiri T, Sullivan JS. Recent advances in the early treatment of cystic fibrosis: bridging the gap to highly effective modulator therapy. Pediatr Pulmonol 2022: 57 Suppl 1:S60-74. doi: 10.1002/ppul.25660. PMID 34473419.
- Lahiri T, Hempstead SE, Brady C, Cannon CL, Clark K, Condren ME, Guill MF, Guillerman RP, Leone CG, Maguiness K, Monchil L, Powers SW, Rosenfeld M, Schwarzenberg SJ, Tompkins CL, Zemanick ET, Davis SD. Clinical practice guidelines from the Cystic Fibrosis Foundation for preschoolers with cystic fibrosis. Pediatrics 2016 : 137(4): e20151784. PMID 27009033.
- Lahiri T, Guillet A, Diehl S, Ferguson MA. High dose ibuprofen is not associated with increased biomarkers of kidney injury in patients with cystic fibrosis. Pediatr Pulmonol 2014: 49:148-53. PMID 23532925.
- Hopkins A, Lahiri T, Salerno R, Heath BW. Changing epidemiology of life-threatening upper airway infections- the re-emergence of bacterial tracheitis. Pediatrics 2006: 118 (4): 1418-1421. PMID 17015531.